ArticleJCO precision oncology2024

Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib.

Andrew T Kuykendall et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.